As previously reported, Leerink upgraded Myriad Genetics to Outperform from Market Perform with a price target of $35, up from $25. The firm believes the risk/reward is skewed to the positive and downside is low at current valuations with Myriad Genetics’ transformation finally working. The company has outlined a 10% growth CAGR, which Leerink believes is conservative as the company has now beaten consensus revenue estimates in 9 of the past 12 quarters under CEO Paul Diaz.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
- Is MYGN a Buy, Before Earnings?
- New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
- Myriad Genetics announces new study published in Prenatal Diagnosis
- Myriad reports results from real-world study of patients with depression